TICKERNERD
Menu
ALXOALXOHealthcare · Biotechnology

ALXO Stock Forecast: ALX Oncology Holdings, Inc. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$1.25
+5.93% on the day

The 7 Wall Street analysts covering ALX Oncology Holdings, Inc. hold a median 12-month price target of $4 — +220.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$174.2M
Ticker Nerd rank
57 / 100
Median analyst target
$4.00
Analysts covering
7
Revenue$0.0
Operating income−$18.3M
Net income−$18.0M
Free cash flow−$16.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.5%
1M
−32.1%
YTD
+10.6%
1Y
−35.6%
From 52W high
−51.9%
From 52W low
+15.7%
$1.08
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALXO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ALX Oncology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
71
Size
70
Revisions
65
Volatility
63
Growth
50
Issuance
48
Accruals
47
Quality
42
Value
37

Momentum (71): The shares have been drifting up relative to others.

Value (37): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALXO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALXO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ALXOHigh $6.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $4.00Median $4.00High $6.00

The green dot is the last close — the median target sits +220.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Mar 2026Wells FargoInitiatesOverweight$5.00
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
5 Feb 2026Piper SandlerMaintainsOverweight—
21 May 2025UBSMaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025StifelMaintainsHold—
6 Mar 2025JefferiesUpgradeBuy—
6 Mar 2025Piper SandlerMaintainsOverweight—
27 Jan 2025UBSMaintainsBuy—
24 Jan 2025Cantor FitzgeraldReiteratesOverweight—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024JefferiesDowngradeHold—
18 Dec 2024Cantor FitzgeraldReiteratesOverweight—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024Cantor FitzgeraldReiteratesOverweight—
16 Aug 2024UBSMaintainsBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024Cantor FitzgeraldReiteratesOverweight—
9 Aug 2024StifelReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALXO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALXO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Oct 2026, ALX Oncology Holdings, Inc. returned −35.6% against +17.3% for the S&P 500, dividends included.

ALXO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ALXOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALXO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

ALX Oncology Holdings, Inc. (ALXO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 68% of US stocks

EV / EBITDA
−0.4×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.6%

Higher than 16% of US stocks

Return on assets
−40.4%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ALX Oncology Holdings, Inc. (ALXO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ALX Oncology Holdings, Inc. has a market value of $174.2M and an enterprise value of $29.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$80.9M.

  • Diluted earnings per share, trailing twelve months: $−1.13.

  • Free cash flow in the twelve months to 30 June 2026: −$71.0M.

  • Shares outstanding: 138.2M.

  • Trailing P/E: −0.7×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ALX Oncology Holdings, Inc. employs 48 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

ALXO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALXOALX Oncology Holdings, Inc.$174.2M
57
CUECue Biopharma, Inc.$162.2M
36
PEPGPepGen Inc.$164.8M
51
VRXAVERAXA Biotech AG$161.0M
23
CNTNCanton Strategic Holdings, Inc.$160.4M
11
MDWDMediWound Ltd.$160.3M
29
CHRSCoherus Oncology, Inc.$159.9M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ALX Oncology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALXO news & analysis

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

GlobeNewsWire · 28 Sept 2026positive

ALX Oncology announced a Nature Medicine publication of ASPEN-06 Phase 2 clinical data for evorpacept in HER2-positive gastric cancer, reporting a 40.3% objective response rate with the evorpacept combination versus 26.6% for control, and higher response rates among patients with high CD47 expression and retained HER2-positive disease.

Why it matters — The peer-reviewed publication of Phase 2 efficacy data provides evidence for evorpacept's potential in HER2-positive gastric cancer, particularly in patients with high CD47 expression.

ALX Oncology to Present at Upcoming Investor Conferences in September

GlobeNewsWire · 2 Sept 2026neutral

ALX Oncology announced that its leadership will participate in fireside chats at three upcoming investor conferences in September. The announcement was made by the clinical-stage biotechnology company on September 2, 2026.

Why it matters — This conference participation offers ALX Oncology an opportunity to present its oncology pipeline and engage with the investment community, which could raise visibility for the company.

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research compares the year-to-date performance of ALX Oncology Holdings (ALXO) and Medpace (MEDP) against their medical sector. The piece examines whether ALXO and MEDP have outpaced their sector peers so far this year.

Why it matters — The article is relevant to ALXO watchers because it assesses how the company's stock has performed relative to both a peer and its medical sector year-to-date.

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 6 Aug 2026positive

ALX Oncology Holdings reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company said it remains on track for a mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast trial of evorpacept in HER2-positive metastatic breast cancer, presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026, noted enrollment momentum in the Phase 1 trial of ALX2004 with initial safety data expected in the second half of 2026, and announced leadership appointments including Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel.

Why it matters — The update outlines progress across ALX Oncology's key clinical programs and leadership team, giving watchers a factual snapshot of the company's pipeline milestones and corporate developments.

FAQ

Frequently asked questions about ALXO stock

What is the ALXO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering ALX Oncology Holdings, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALXO stock a buy right now?

Of the 7 analysts covering ALX Oncology Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ALX Oncology Holdings, Inc. 57 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALXO?

As at 8 Oct 2026, ALX Oncology Holdings, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (71 of 100).

Will ALXO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +220.0% from the last close, and Ticker Nerd's factor model ranks ALX Oncology Holdings, Inc. 57 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALXO stock forecast for 2030?

No analyst covering ALX Oncology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALXO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has ALXO stock performed over the past year?

ALX Oncology Holdings, Inc. returned -35.6% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ALX Oncology Holdings, Inc. do?

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer.

What is the latest news on ALXO?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer". ALX Oncology announced a Nature Medicine publication of ASPEN-06 Phase 2 clinical data for evorpacept in HER2-positive gastric cancer, reporting a 40.3% objective response rate with the evorpacept combination versus 26.6% for control, and higher response rates among patients with high CD47 expression and retained HER2-positive disease.

Company

About ALX Oncology Holdings, Inc.

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications. The company’s pipeline also includes ALX2004, an epidermal growth factor receptor-targeted antibody-drug conjugate under development for EGFR-expressing tumors. ALX Oncology’s work centers on protein engineering, combination therapy research, and clinical studies aimed at addressing difficult-to-treat cancers. Based in South San Francisco, California, the company operates within the broader oncology drug development market and collaborates with clinical trial sites and research partners to advance its product candidates.

CEO Mr. Jason W. Lettmann · 48 employees · United States · https://www.alxoncology.com